According to FDA MedWatch, Nipro Diagnostics has initiated a voluntary recall and replacement of a limited number of TRUEbalance and TRUEtrack Blood Glucose Meters distributed both in the United States and outside the United States.
Category: Products & Tech
Most of the diabetes products we thought would be introduced in 2013 did not make it to the U.S. market. We're optimistic that some of those products will be available this year. Some, however, like Abbott's Navigator 2, still seem far off.
The two GLP-1 treatments available are sold under the brand names Byetta and Victoza. The drugs, however, are not very popular with consumers, and are not nearly as popular as they deserve to be, according to Edelman. “It’s a case of clinical inertia on behalf of doctors,” Edelman says regarding one reason why more GLP-1 prescriptions aren’t being written.
As 2013 comes to an end, we're taking a look back at our best diabetes articles of the year. From science and technology to personal essays to op-ed, we're been overwhelmed with the quality of our writers' work. We hope you've enjoyed reading as much as we've enjoyed publishing.
The FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has decided (13-1) in favor of Bristol-Myers Squib and AstraZeneca's type 2 diabetes drug, dapagliflozin. The committeee found that the benefits of dapagliflozin use outweigh identified risks and support marketing of dapagliflozin as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
IDegLira is a combination of Tresiba (insulin degludec), a once-daily basal insulin analogue with an ultra-long duration of action, and Victoza (liraglutide), the once-daily human GLP-1 analogue for the treatment of type 2 diabetes.
Sanofi announced the results from the EDITION II study showing that investigational new U300 insulin demonstrated similar blood sugar control as Lantus insulin with 23% fewer night-time lows...
The U.S. FDA has lifted certain restrictions on prescribing and use of the diabetes drug Avandia (rosiglitazone) to reflect new information regarding the cardiovascular risk of the medicine.
The EU's Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted a positive opinion recommending marketing of NovoRapid PumpCart in Europe. NovoRapid PumpCart is a 1.6 ml prefilled insulin pump cartridge containing the rapid-acting insulin NovoRapid...
When it came to using the data the Dexcom CGM was giving me on my blood sugar levels, the first day was a self-induced roller coaster nightmare. What left me feeling so anxious wasn’t actually the number on the screen or the programmed alarms I’d been advised by three experienced, certified diabetes educators to set at 75 mg/dL and 140 mg/dL. Instead, it was the arrows.